IDH1/2

The impact of 2-hydroxyglutarate levels, IDH1/2 mutational status on the outcomes of patients with newly diagnosed acute myeloid…

Anna Bartus , Nov 20, 2018

General AML

Phase II study evaluating azacitidine plus nivolumab in relapsed/refractory acute myeloid leukemia

Anna Bartus , Nov 14, 2018

General AML

Clinical impact of post-remission therapy after MIDAM regimen in patients with acute myeloid leukemia

Cynthia Umukoro , Nov 9, 2018

General AML

Haploidentical transplantation may be a feasible option for patients with relapsed/refractory acute myeloid leukemia

Anna Bartus , Nov 7, 2018

General AML

Three novel regimens for relapsed/refractory acute myeloid leukemia – a randomized phase II trial

Anna Bartus , Nov 5, 2018

General AML

Venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia

Cynthia Umukoro , Nov 2, 2018

NPM1,   FLT3

Prognostic impact of FLT3-ITD allelic ratio and NPM1 mutation in acute myeloid leukemia

Cynthia Umukoro , Oct 31, 2018

General AML

Phase II study on fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia

Anna Bartus , Oct 29, 2018

General AML

The clinical impact of SAMHD1 in patients with acute myeloid leukemia receiving consolidation chemotherapy with high-dose…

Cynthia Umukoro , Oct 25, 2018

TP53

Subclonal TP53 mutations in acute myeloid leukemia

Cynthia Umukoro , Oct 23, 2018